Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Advances in CRM Technology

Executive Summary

At this year's Heart Rhythm Society meeting, companies showcased a number of technologies designed to make cardiac rhythm management (CRM) devices, such as implantable cardioverter defibrillators and pacemakers, safer, more effective, and easier to implant. In addition, there were some early-stage presentations on promising next-generation CRM technologies involving leadless and rechargeable systems-paradigm changing advances.

You may also be interested in...



EuroPACE Highlights: AF Cath Ablation Interest Heats Up

Catheter ablation dominated the biannual EuroPACE meeting held in Lisbon at the end of June. In addition to the range of manual catheter ablation systems, remote catheter navigation and mapping also attracted large audiences.

In Brief

Brief summaries of recent developments in the medical device industry.

Risk Stratification for ICDs: The Debate Rages On

The clinical trials MADIT II and SCD-HeFT definitively proved the benefit of ICDs for preventing the risk of sudden cardiac death and paved the way for reimbursement. But now that the excitement has died down, the confusion has set in. Clinicians aren't entirely sure in which real-world patients to implant devices. The debate about the proper methods of risk stratifying patients for ICD implantation rages on.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035007

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel